Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system

High-grade serous ovarian carcinoma (HGSOC) is a genomically unstable malignancy responsible for over 70% of all deaths due to ovarian cancer. With roughly 50% of all HGSOC harboring defects in the homologous recombination (HR) DNA repair pathway (e.g., BRCA1/2 mutations), the introduction of poly A...

Full description

Bibliographic Details

Main Authors:	Nirashaa T. Bound, Cassandra J. Vandenberg, Apriliana E. R. Kartikasari, Magdalena Plebanski, Clare L. Scott
Format:	Artigo
Language:	Inglês
Published:	Frontiers Media S.A. 2022-09-01
Series:	Frontiers in Genetics
Subjects:	high-grade serous ovarian carcinoma poly ADP-ribose polymerase inhibitors epigenetics immunotherapy combination (combined) therapy clinical trials
Online Access:	https://www.frontiersin.org/articles/10.3389/fgene.2022.886170/full
Tags:	Add Tag No Tags, Be the first to tag this record!